相关实验视频

Updated: May 5, 2026

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

在中国批准创新的放射性药品的途径

Shuxian An¹, Lu Wang², Fang Xie³

¹Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

|May 8, 2024

概括

中国中国中国中国.

科学领域:

核医学是一种核医学.
放射性药物科学是一种放射性药物科学.
药物监管事务药物监管事务

背景情况:

自20世纪50年代末以来,放射性药物一直是中国临床核医学的组成部分.
中国拥有发达的放射性药品生产和管理系统,经济增长推动的市场迅速扩大.
尽管市场扩张,但研究,投资,放射性核素供应和监管缺陷等挑战不足,阻碍了发展.

研究的目的:

审查中国国家医药品管理局 (NMPA) 对新型放射性药物的批准程序.
概述中国放射性药物研发 (R&D) 的现状.
为推进放射性药物创新提供实际建议.

主要方法:

审查影响放射性药品的监管改革和国家发展计划.
对中国放射性药物研发和临床转化现状的分析.
综合了该领域从业人员的专家观点.

主要成果:

自2015年以来最近的监管改革和"医学同位素中长期发展计划 (2021-2035) "为放射性药物发展创造了有利的环境.
放射性药物的临床前和临床翻译在中国正在迅速发展.
尽管取得了进展,但持续存在的挑战需要战略解决方案.

结论:

中国的放射性药物行业正在经历显著的增长和演变,受到政策变革的支持.
解决现有挑战对于进一步的创新和临床应用至关重要.
合作讨论和实际建议对于中国放射性药物的未来至关重要.

关键词:

这是NMPANMPANMPA.诊断诊断诊断诊断诊断诊断药物的批准药物的批准放射性药物制品放射性药物制品治疗疗法治疗疗法治疗疗法

更多相关视频

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of ⁶⁸Ga-Labelled Nano Molecules

Published on: October 4, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...